Spyre Therapeutics, Inc (SYRE)
NASDAQ:SYRE
Want to see SYRE full AI Analyst Report?
SYRE Stock Chart & Stats
$73.01
-$0.27(-1.11%)
At close: 4:00 PM EST
$73.01
-$0.27(-1.11%)
Day’s Range― - ―
52-Week Range$13.93 - $79.54
Previous CloseN/A
Volume84.75K
Average Volume (3M)1.03M
Market Cap
$6.01B
Enterprise Value$4.34B
Total Cash (Recent Filing)$741.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 06, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding86,841,255
10 Day Avg. Volume810,332
30 Day Avg. Volume1,025,042
Financial Highlights & Ratios
PEG Ratio1.94
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue47.98
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.57
Forecast
1Y Price Target
$95.86Price Target Upside31.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetZero reported debt and substantial equity create durable financial flexibility, lowering insolvency risk and allowing management to prioritize R&D and clinical milestones over near-term cash preservation. This balance-sheet strength supports multi-stage drug development and strategic optionality for 2–6 months and beyond.
Completed $463.5M FinancingA large equity raise materially extends runway to fund clinical development, manufacturing readiness, and Phase 3 preparations. By pre-funding key program work, the company reduces execution risk on planned trials and improves negotiating leverage for partnerships or licensing over the coming months.
Positive Phase 2 SKYLINE ResultsRobust Phase 2 topline efficacy and good tolerability provide durable proof-of-concept for SPY001, supporting its use as a backbone in combination regimens. Positive clinical data raise the probability of successful late-stage outcomes, strengthen partnering prospects, and help establish competitive differentiation in IBD.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this scale means the company will likely need additional financings or partnerships to complete multiple development programs. High burn constrains strategic flexibility and elevates dilution and execution risk if timelines extend or trials require extra resources.
Deep Ongoing LossesLarge recurring net losses indicate the business has not yet converted R&D investment into sustainable revenues or margins. Until commercial products or stable partnership revenues emerge, the company will lack internal profit generation, keeping it dependent on external capital and increasing sensitivity to financing market conditions.
ATM Program PausedPausing the ATM reduces the firm's ability to access opportunistic, incremental equity capital quickly. Even with a recent large financing, the lost near-term tactical funding mechanism can limit agility to respond to unexpected trial costs or accelerate programs without triggering larger financings that cause more dilution.
Spyre Therapeutics News
SYRE FAQ
What was Spyre Therapeutics, Inc’s price range in the past 12 months?
Spyre Therapeutics, Inc lowest stock price was $13.93 and its highest was $79.54 in the past 12 months.
What is Spyre Therapeutics, Inc’s market cap?
Spyre Therapeutics, Inc’s market cap is $6.01B.
When is Spyre Therapeutics, Inc’s upcoming earnings report date?
Spyre Therapeutics, Inc’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Spyre Therapeutics, Inc’s earnings last quarter?
Spyre Therapeutics, Inc released its earnings results on May 05, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.666 by -$0.074.
Is Spyre Therapeutics, Inc overvalued?
According to Wall Street analysts Spyre Therapeutics, Inc’s price is currently Undervalued.
Does Spyre Therapeutics, Inc pay dividends?
Spyre Therapeutics, Inc does not currently pay dividends.
What is Spyre Therapeutics, Inc’s EPS estimate?
Spyre Therapeutics, Inc’s EPS estimate is -0.73.
How many shares outstanding does Spyre Therapeutics, Inc have?
Spyre Therapeutics, Inc has 86,841,255 shares outstanding.
What happened to Spyre Therapeutics, Inc’s price movement after its last earnings report?
Spyre Therapeutics, Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.666. Following the earnings report the stock price went up 2.72%.
Which hedge fund is a major shareholder of Spyre Therapeutics, Inc?
Currently, no hedge funds are holding shares in SYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spyre Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.86 (31.29% Upside)
$95.86 (31.29% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 296.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
343.69%
12-Months-Change
Fundamentals
Return on Equity
-31.25%
Trailing 12-Months
Asset Growth
34.08%
Trailing 12-Months
Company Description
Spyre Therapeutics, Inc
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE Stock 12 Month Forecast
Average Price Target
$95.86
▲(31.29% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Oculis Holding
―
Upstream Bio, Inc.
―
Ownership Overview
6.50% Insiders
22.60% Mutual Funds
48.95% Other Institutional Investors
10.76% Public Companies and Individual Investors
Options Prices
Currently, No data available
---